View More Recent Stories

Apr 8, 2022 08:30AM KAZIA THERAPEUTICS ANNOUNCES PRECLINICAL DATA PRESENTED AT AACR CONFERENCE BY JOHNS HOPKINS UNIVERSITY SHOWING ACTIVITY OF PAXALISIB IN PAEDIATRIC BRAIN TUMOURS
Apr 8, 2022 08:00AM TWO ABSTRACTS AT AACR CONFERENCE PRESENT DETAILED STUDY DESIGN AND INNOVATIVE BIOMARKER STRATEGY FOR ONGOING PHASE I STUDY OF EVT801 IN ADVANCED CANCER
Mar 21, 2022 08:00AM KAZIA TO PRESENT AT UPCOMING INVESTOR CONFERENCE AND AACR ANNUAL SCIENTIFIC MEETING
Feb 28, 2022 08:00AM PHASE II CLINICAL STUDY AT WEILL CORNELL MEDICAL CENTER INVESTIGATING PAXALISIB IN COMBINATION WITH METFORMIN AND A KETOGENIC DIET ENROLLS FIRST PATIENT
Feb 7, 2022 08:00AM KAZIA THERAPEUTICS TO PRESENT AT BIO CEO CONFERENCE
Jan 25, 2022 08:00AM KAZIA THERAPEUTICS TO PARTICIPATE IN EDISON GROUP'S GLOBAL HEALTHCARE 'OPEN HOUSE' VIRTUAL CONFERENCE
Jan 7, 2022 08:00AM KAZIA THERAPEUTICS TO PRESENT AT HC WAINWRIGHT BIOCONNECT CONFERENCE
Dec 13, 2021 11:06AM Kazia Therapeutics (KZIA) Appoints Karen Krumeich as CFO
Dec 13, 2021 11:00AM KAZIA THERAPEUTICS APPOINTS KAREN KRUMEICH AS CHIEF FINANCIAL OFFICER
Nov 29, 2021 08:00AM GBM AGILE Opens to Paxalisib in Canada
Nov 15, 2021 11:01AM Kazia Therapeutics (KZIA) Appoints John Friend as Chief Medical Officer
Nov 15, 2021 11:00AM Kazia Therapeutics Appoints John Friend, MD, as Chief Medical Officer
Nov 11, 2021 08:00AM PNOC Study in Childhood Brain Cancer Enrols First Patient
Oct 6, 2021 10:00AM Kazia Therapeutics to Present at LD Micro Main Event
Sep 10, 2021 12:30PM Kazia Therapeutics to Present at HC Wainwright 23rd Annual Global Investment Conference
Jul 21, 2021 10:00AM Kazia Calls for Increased Focus on Brain Cancer Research this GBM Awareness Day
Jun 30, 2021 10:00AM Kazia Provides Progress Update on Paxalisib and EVT801 Clinical Programs
Jun 15, 2021 10:01AM Kazia (KZIA) Enters Clinical Collaboration With Cornell University for Phase II Clinical Study Using Paxalisib in Combination With Ketogenic Diet for Glioblastoma
Jun 15, 2021 10:00AM Kazia Enters Clinical Collaboration With Cornell University for Phase II Clinical Study Using Paxalisib in Combination With Ketogenic Diet for Glioblastoma
Jun 7, 2021 08:00AM Study of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First Patient
Jun 3, 2021 07:00AM Kazia Therapeutics to Present at LD Micro Invitational XI
Apr 19, 2021 05:36AM Kazia Licenses Global Rights to EVT801, a Novel, First-in-Class, Clinic-Ready, VEGFR3 Inhibitor, from Evotec SE
Mar 30, 2021 07:41AM Kazia Therapeutics (KZIA) has signed agreement for Greater China rights to paxalisib with Simcere Pharmaceuticals
Mar 30, 2021 07:40AM Kazia Therapeutics (KZIA): Paxalisib Chinese Rights Licensed
Sep 2, 2020 10:15AM Edison issues ADR outlook on Kazia Therapeutics (KZIA)
Jan 13, 2020 07:55AM Edison issues ADR update on Kazia Therapeutics (KZIA)
Dec 2, 2019 08:45AM Edison issues ADR outlook on Kazia Therapeutics (KZIA)
Apr 1, 2019 07:40AM Edison issues ADR update on Kazia Therapeutics (KZIA)
Oct 29, 2018 09:29AM Edison issues ADR update on Kazia Therapeutics (KZIA)
View More Recent Stories